Skip to content

Study · Non-randomized trial · n = 20 · 1997

5 results

Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.

Grottoli S, Razzore P, Arvat E, Oleandri SE, Rossetto R, Ciccarelli E, Camanni F, Ghigo E

Journal of endocrinological investigation1 Nov 1997Cited by 1 (Europe PMC)

PMID9438917 (opens in a new tab)DOI10.1007/bf03346916 (opens in a new tab)PepBankPUB-09438917
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    The GH response to hexarelin was lower in patients with hyperprolactinemia than in normal women (p < 0.03).

    In plain wordsPatients with high prolactin had a smaller growth hormone response to hexarelin than normal women.

    Peptide
    Hexarelin
    Outcome
    DecreaseGH response to hexarelin, hyperprolactinemia vs normal women
    Study

    n = 20

    Comparator
    Normal age-matched women
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenous · single doseAs given in this study (human).

    Source sentences

    Summary
    In HPRL the GH responses to GHRH and HEX were lower than those that in NW (p < 0.03) while that to GHRH + ARG was similar in both groups.
    1 context sentence
    Summary · context
    in 12 HPRL normal weight patients (age 28.6 +/- 2.6 yr, BMI 23.1 +/- 1.1 kg/m2) and 8 NW (27.2 +/- 0.8 yr, 22.8 +/- 0.8 kg/m2)
  2. 02HumanNon-randomized trialActivity measurement

    In patients with hyperprolactinemia, the GH response to hexarelin was higher than that to GHRH (p < 0.03).

    In plain wordsIn patients with high prolactin, hexarelin raised growth hormone more than GHRH did.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH response to hexarelin vs GHRH in hyperprolactinemia
    Study

    n = 12

    Comparator
    GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenous · single doseAs given in this study (human).

    Measurements

    GH AUC
    1586.5 micrograms 90 min/l
    hexarelin, hyperprolactinemia
    GH AUC
    894.7 micrograms 90 min/l
    GHRH, hyperprolactinemia

    Source sentences

    Summary
    In HPRL the GH response to GHRH (894.7 +/- 242.4 micrograms 90 min/l) was lower (p < 0.03) than that to HEX
    2 context sentences
    Summary · context
    (1586.5 +/- 251.3 micrograms 90 min/l)
    Summary · context
    in 12 HPRL normal weight patients (age 28.6 +/- 2.6 yr, BMI 23.1 +/- 1.1 kg/m2) and 8 NW (27.2 +/- 0.8 yr, 22.8 +/- 0.8 kg/m2)
  3. 03HumanNon-randomized trialActivity measurement

    In patients with hyperprolactinemia, the GH response to hexarelin was lower than that to GHRH plus arginine (p < 0.03).

    In plain wordsIn patients with high prolactin, hexarelin raised growth hormone less than GHRH plus arginine did.

    Peptide
    Hexarelin
    Outcome
    DecreaseGH response to hexarelin vs GHRH plus arginine in hyperprolactinemia
    Study

    n = 12

    Comparator
    GHRH plus arginine
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenous · single doseAs given in this study (human).

    Source sentences

    Summary
    In HPRL the GH response to GHRH (894.7 +/- 242.4 micrograms 90 min/l) was lower (p < 0.03) than that to HEX (1586.5 +/- 251.3 micrograms 90 min/l) and both were lower (p < 0.03) than that to GHRH + ARG (4468.8 +/- 941.7 micrograms 90 min/l).
    1 context sentence
    Summary · context
    in 12 HPRL normal weight patients (age 28.6 +/- 2.6 yr, BMI 23.1 +/- 1.1 kg/m2) and 8 NW (27.2 +/- 0.8 yr, 22.8 +/- 0.8 kg/m2)
  4. 04HumanNon-randomized trialActivity measurement

    In normal women, the GH response to hexarelin was higher than that to GHRH.

    In plain wordsIn normal women, hexarelin raised growth hormone more than GHRH did.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH response to hexarelin vs GHRH in normal women
    Study

    n = 8

    Comparator
    GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenous · single doseAs given in this study (human).

    Measurements

    GH AUC
    3216.6 micrograms 90 min/l
    hexarelin, normal women
    GH AUC
    1299.5 micrograms 90 min/l
    GHRH, normal women

    Source sentences

    Summary
    In NW the GH response to GHRH (AUC: 1299.5 +/- 186.9 micrograms 90 min/l) was lower (p < 0.02) than those to GHRH + ARG (5252.7 +/- 846.3 micrograms 90 min/l) and HEX 3216.6 +/- 462.3 micrograms 90 min/l) which, in turn, were similar.
    1 context sentence
    Summary · context
    in 12 HPRL normal weight patients (age 28.6 +/- 2.6 yr, BMI 23.1 +/- 1.1 kg/m2) and 8 NW (27.2 +/- 0.8 yr, 22.8 +/- 0.8 kg/m2)
  5. 05HumanNon-randomized trialActivity measurement

    In normal women, the GH response to hexarelin was similar to that to GHRH plus arginine.

    In plain wordsIn normal women, hexarelin and GHRH plus arginine raised growth hormone by a similar amount.

    Peptide
    Hexarelin
    Outcome
    No significant changeGH response to hexarelin vs GHRH plus arginine in normal women
    Study

    n = 8

    Comparator
    GHRH plus arginine
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenous · single doseAs given in this study (human).

    Source sentences

    Summary
    In NW the GH response to GHRH (AUC: 1299.5 +/- 186.9 micrograms 90 min/l) was lower (p < 0.02) than those to GHRH + ARG (5252.7 +/- 846.3 micrograms 90 min/l) and HEX 3216.6 +/- 462.3 micrograms 90 min/l) which, in turn, were similar.
    1 context sentence
    Summary · context
    in 12 HPRL normal weight patients (age 28.6 +/- 2.6 yr, BMI 23.1 +/- 1.1 kg/m2) and 8 NW (27.2 +/- 0.8 yr, 22.8 +/- 0.8 kg/m2)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.